NEW YORK (GenomeWeb News) - Caliper Life Sciences today said that its third-quarter revenues rose 38 percent on strong microfluidics sales and net loss fell 82 percent.
 
For the three months ended Sept. 30, Caliper’s revenues increased to $36.7 million from $26.5 million year over year. The firm attributed the growth to last year’s acquisition of Xenogen, its drug-discovery services, and increased license fees from its microfluidic products.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.